Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zanidatamab with palbociclib plus fulvestrant in HER2-positive, HR-positive advanced breast cancer
2023-508135-30-00Phase 2Completed
- Sponsor
- Jazz Pharmaceuticals plc
- Start
- Sep 2024
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 3
01
Overview
Phase 2, open-label trial of zanidatamab in breast cancer (2 cohorts), sponsored by Jazz Pharmaceuticals plc. Primary endpoints: Part 1 dose-limiting toxicities and safety, Adverse events of special interest and 2 more. Started Sep 2024; status: completed.
02
Drugs
zanidatamab
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2023-508135-30-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-508135-30-00.